Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax, using the contact information at the bottom of this page.
FDA Requires Boxed Warning for Promethazine Hydrochloride Injection[ARCHIVED]
FDA news release (9/16/2009)
- Information for Healthcare Professionals: Intravenous Promethazine and Severe Tissue Injury, Including Gangrene [ARCHIVED]
- Information for Healthcare Professionals: Promethazine (marketed as Phenergan and generic products) [ARCHIVED]